These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18855914)

  • 1. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.
    Saxena V; Panicucci R; Joshi Y; Garad S
    J Pharm Sci; 2009 Jun; 98(6):1962-79. PubMed ID: 18855914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of preformulation on drug development.
    Bharate SS; Vishwakarma RA
    Expert Opin Drug Deliv; 2013 Sep; 10(9):1239-57. PubMed ID: 23534681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ask the experts: the challenges and benefits of flow chemistry to optimize drug development.
    Anderson N; Gernaey KV; Jamison TF; Kircher M; Wiles C; Leadbeater NE; Sandford G; Richardson P
    Future Med Chem; 2012 Sep; 4(14):1779-89. PubMed ID: 23043475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the most important approach in current drug discovery: doing the right things or doing things right?
    Elebring T; Gill A; Plowright AT
    Drug Discov Today; 2012 Nov; 17(21-22):1166-9. PubMed ID: 22569181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the development scientist in compound lead selection and optimization.
    Venkatesh S; Lipper RA
    J Pharm Sci; 2000 Feb; 89(2):145-54. PubMed ID: 10688744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development: from concept to marketing!
    Tamimi NA; Ellis P
    Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
    Campbell JB
    IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: Why Pharmaceutical Scientists in Early Drug Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates.
    Landis MS; Bhattachar S; Yazdanian M; Morrison J
    AAPS PharmSciTech; 2018 Jan; 19(1):1-10. PubMed ID: 28755053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Q&A: Bernard Munos.
    Bender E
    Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
    [No Abstract]   [Full Text] [Related]  

  • 15. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based drug development: a rational approach to efficiently accelerate drug development.
    Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
    Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
    Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
    Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early implementation of QbD in biopharmaceutical development: a practical example.
    Zurdo J; Arnell A; Obrezanova O; Smith N; Gómez de la Cuesta R; Gallagher TR; Michael R; Stallwood Y; Ekblad C; Abrahmsén L; Höidén-Guthenberg I
    Biomed Res Int; 2015; 2015():605427. PubMed ID: 26075248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.